Literature DB >> 26766890

Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing: The Pressure Is on P&T Committees to Monitor Utilization.

Stephen Barlas.   

Abstract

The agreement between Harvard Pilgrim and Amgen on a "pay for performance" deal involving evolocumab could encourage other manufacturers, health plans, and policy-makers to press for value-based pricing as drug costs continue to escalate.

Entities:  

Year:  2016        PMID： 26766890      PMCID： PMC4699485     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  3 in total

1.  Predicting the Overuse of PCSK-9 Inhibitors.

Authors:  Rene Rodriguez-Gutierrez; Nilay D Shah; Victor M Montori
Journal:  JAMA       Date:  2015-11-10       Impact factor: 56.272

2.  Cancer drugs in the United States: Justum Pretium--the just price.

Authors:  Hagop M Kantarjian; Tito Fojo; Michael Mathisen; Leonard A Zwelling
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

3.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

Authors:  Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391
  3 in total
  1 in total

Review 1.  Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict.

Authors:  Hans-Georg Eichler; Mark Trusheim; Brigitte Schwarzer-Daum; Kay Larholt; Markus Zeitlinger; Martin Brunninger; Michael Sherman; David Strutton; Gigi Hirsch
Journal:  Clin Pharmacol Ther       Date:  2021-11-17       Impact factor: 6.903
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.